Apogee Therapeutics, Inc. (APGE) Stock Analysis
Healthcare · Biotechnology · NasdaqGM
Apogee Therapeutics, Inc. (APGE) posted $0 in revenue for fiscal 2025, with a net loss of $255.84M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. has grown revenue from $0 to $0 over the last 4 fiscal years.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Apogee Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Apogee Therapeutics, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-39.78M | $-83.98M | $-182.15M | $-255.84M |
| Net margin | — | — | — | — |
Source: Apogee Therapeutics, Inc. SEC filings (10-K).
Apogee Therapeutics, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 42.5% over 3 years (48M → 68.4M) — existing holders' stakes are being diluted.
Explore 4 years of Apogee Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track APGE in your portfolio →
Apogee Therapeutics, Inc. financial history by metric
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Apogee Therapeutics, Inc. — frequently asked questions
What is Apogee Therapeutics, Inc.'s revenue?
Apogee Therapeutics, Inc. (APGE) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Apogee Therapeutics, Inc. profitable?
No — APGE reported a net loss of $-255.84M in fiscal 2025.
What is APGE's P/E ratio?
Apogee Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Apogee Therapeutics, Inc. have?
As of fiscal year 2025, APGE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Apogee Therapeutics, Inc.'s market cap?
Apogee Therapeutics, Inc. (APGE) has a market capitalization of about $6.38B, based on the latest data in our nightly-refreshed cache.
When does Apogee Therapeutics, Inc.'s fiscal year end?
APGE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Apogee Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.